Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts

Cale D. Fahrenholtz, Pedro J. Beltran, Kerry L. Burnstein

Research output: Contribution to journalArticle

18 Scopus citations

Fingerprint Dive into the research topics of 'Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts'. Together they form a unique fingerprint.

Medicine & Life Sciences